Uncategorized

argenx announced that members of management will participate in several upcoming investor conferences in September:

Shanghai Fosun Pharmaceutical Co., Ltd.* announced its 2023 Interim Results for the first half of 2023.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company’s interim report for the period January-June 2023, has been published.

Mindray, a global leader in providing advanced medical device solutions, has unveiled upgrades to its A7 and A5 anaesthesia systems under the A Series Anaesthesia.

Akeso released its 2023 interim performance: the Company achieved financial profitability for the first time in the first half of 2023, reaping success in new drug development, commercialization and globalization.

BioSkryb Genomics announced a partnership with Research Instruments Pte Ltd, a premier distributor for genomic and life science research products in Southeast Asia, to distribute BioSkryb’s ResolveDNA® and ResolveOME™ single cell amplification tools throughout Singapore and Southeast Asia.

Warning signs that preceded the current economic squeeze in the biopharma sector were not heeded by investors seeking rapid profits. Now, biotechs interested in making the leap to the public markets must get creative.

Lupin Pharmaceuticals’ recall of Tydemy birth control is the latest in a string of problems with India-based generic drug manufacturers.

The program aims to cut the time physicians spend searching multiple systems to understand the cardiac history of AFib patients.

The Cincinnati-based health system is alleging the Elevance subsidiary owes $93 million following four years of contract disputes.